Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo Nordisk A/S (NOVO:CA) Discusses Obesity and Diabetes Portfolio Progress and Pill Launch Milestones at R&D Event Transcript
02:31am, Monday, 08'th Jun 2026
Novo Nordisk A/S (NOVO:CA) Discusses Obesity and Diabetes Portfolio Progress and Pill Launch Milestones at R&D Event Transcript
The Wegovy pill is still dominating the GLP-1 pill market
07:35pm, Sunday, 07'th Jun 2026
It has remained a top choice among Americans trying to lose weight even after the launch of Foundayo, Eli Lilly's GLP-1 pill.
80% of Wegovy Pill Users Never Took a Weight Loss Drug Before. Does This Number Change the Entire Novo Nordisk Bear Case?
08:45am, Sunday, 07'th Jun 2026
Novo Nordisk has reported strong initial sales for the pill-based version of its GLP-1 weight loss drug, Wegovy. Sales do not appear to be coming at the expense of Novo's previously released injectabl
Novo's Wegovy Pill Isn't Just Beating Expectations -- It's Obliterating Them. Is the Beaten-Down Stock a Buy Now?
09:15am, Saturday, 06'th Jun 2026
Wall Street likes stories, and a big one today is the huge demand for GLP-1 weight-loss drugs. Novo Nordisk got off to an early lead, but Eli Lilly is now the most noted name in the space.
Novo And Lilly Push Beyond US As Only 1%-2% Use Obesity Drugs Globally
01:31pm, Friday, 05'th Jun 2026
Novo Nordisk (NVO) and Eli Lilly (LLY) are preparing for the next stage of the obesity-drug race, with both companies looking beyond the US for growth as cost r
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Friday, 05'th Jun 2026
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Here's What I Think Is Really Going on With Novo Nordisk Stock
02:45pm, Wednesday, 03'rd Jun 2026
Novo Nordisk lost momentum in the GLP-1 market. The company's deep pipeline could allow it to bounce back.
Novo Nordisk is taking its Wegovy pill beyond the U.S.
11:07am, Wednesday, 03'rd Jun 2026
Novo Nordisk (NVO) is starting to take its Wegovy pill global, launching the oral weight loss drug in the United Arab Emirates after getting regulatory approval
Live Nasdaq Composite: Markets Take a Breather amid Stellar AI Earnings Cycle
09:03am, Wednesday, 03'rd Jun 2026
Live Updates The analyst who called NVIDIA in 2010 just named his top 10 AI stocksThis analyst's 2025 picks are up 106% on average. He just named his top 10 stocks to buy in 2026. Get them here FREE.
5 Stocks Set to Cash in on The Next 90-Million Customer Industry. (It's Not AI)
08:38am, Wednesday, 03'rd Jun 2026
Wells Fargo's chief agriculture economist Dr. Michael Swanson told Bloomberg Businessweek on May 29 that GLP-1 weight-loss drugs (Ozempic, Wegovy, Mounjaro, Zepbound) will eventually match statins at
Novo Nordisk: Deeply Undervalued With A Return To Growth In 2027
08:03am, Wednesday, 03'rd Jun 2026
Novo Nordisk is rated a strong buy, offering a 4.2% yield and trading at a 40% discount to fair value. NVO's growth is temporarily pressured by U.S. price cuts and competition, but volume and product
Wall Street Breakfast Podcast: Bitcoin's Great Withdrawal
06:33am, Wednesday, 03'rd Jun 2026
Bitcoin (BTC-USD) underperforms equities amid record ETF outflows and waning institutional demand. MSTR's first Bitcoin sale in nearly four years challenges its 'never sell' narrative, raising questio
Novo Nordisk launches Wegovy in UAE
04:33am, Wednesday, 03'rd Jun 2026
Novo Nordisk is launching its weight-loss drug Wegovy in the United Arab Emirates, it said in a statement on Wednesday.
Novo Nordisk rolls out Wegovy pill in the UAE — its first market outside the U.S.
03:42am, Wednesday, 03'rd Jun 2026
Novo Nordisk is launching weight loss pill Wegovy in the United Arab Emirates, the Danish drugmaker said Wednesday. It marks the pill's first launch outside the U.S. market.
Novo Nordisk Launches Wegovy Weight-Loss Pill in UAE
03:03am, Wednesday, 03'rd Jun 2026
The United Arab Emirates becomes the second country to offer the pill after the drugmaker launched it in the U.S. in early January.
